SHENZHEN, CHINA--(Marketwire - Nov. 22, 2010) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS) (www.htdsmedical.com) announces that the merger negotiations with the Canadian Biotechnology company are proceeding well, and that the merger candidate permitted HTDS to release the name and additional information about the candidate:
The merger candidate, Hb Products Inc., is a Canadian biotechnology company that deals with blood transfusion products. Hb Products Inc. is a biotechnology company that is involved in validating a product that will reduce the major side effects related to transfusions of donated blood or hemoglobin-based blood substitutes.
Hb Products Inc. focuses on treatment of serious harmful side effects existing with the use of stored donor blood, focusing specifically on solving the loss of Nitric Oxide (NO) from the recipients' blood, which creates a hazardous condition called vasoconstriction. The market for these blood products is relatively untapped and highly competitive. Due to the potential market for blood substitutes and the shortfall of available donor blood, several pharmaceutical companies have attempted to gain FDA approval for their products, but none have succeeded as of yet. Hb Products Inc. plans to demonstrate in pre-clinical tests that its product can circumvent the loss of NO from blood and improve the shelf life of stored blood for up to 42 days.
The market value for blood transfusions on the North American market is currently in excess of $14 billion USD.
HTDS sees Hb Products as a perfect fit alongside their current medical subsidiaries Shenzhen Mellow Hope Pharm Industrial Co., Ltd. and Slavica Biochem.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this quarterly report constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.